Clinical and Biological Significance of Hepatoma-Derived Growth Factor in Ewing Sarcoma/PNET
Yang Yang, Hui Li, Fenfen Zhang, Huijuan Shi, Anjia Han. First Affiliated Hospital and Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China
Background: To investigate the clinical significance of hepatoma-derived growth factor (HDGF) in Ewing sarcoma/peripheral primitive neuroectodermal tumours (PNET).
Design: Immunohistochemistry staining was used to detect HDGF and p53 expression in 108 patients with Ewing sarcoma/PNET. Statistical analyses were applied to test the prognostic and diagnostic associations. The cell proliferation, apoptosis, G1/S transition of cell cycle, migration and invasion, and colony formation of HDGF downregulation in Ewing sarcoma cell was determined.
Results: Our results showed that fifty-five cases (50.9%, 55/108) showed high HDGF expression in Ewing sarcoma/PNET. Seventeen cases (15.7%, 17/108) were p53 positivity. There were significant relationships between HDGF expression and tumor size (p=0.008), metastatic status at initial diagnosis (p=0.027), and p53 expression (p=0.022). Furthermore, there was a positive correlation between high HDGF expression and p53 positive expression in Ewing sarcoma/PNET(p=0.022). Patients with high HDGF expression had shorter overall survival and disease-free survival at 3 or 5 years than those with low HDGF expression, respectively. In addition to distant metastasis, multivariate analysis demonstrated that HDGF expression was an independent strong predictor for OS and DFS in Ewing sarcoma/PNET patients (p=0.002, p<0.001, respectively). HDGF knockdown dramatically inhibited proliferation, migration, invasion, colony formation and G1/S transition of cell cycle, but induced apoptosis in Ewing sarcoma cells.
Conclusions: In conclusion, our results firstly suggest that nuclear HDGF expression is a significant adverse prognostic factor for overall survival and disease-free survival in patients with Ewing sarcoma/PNET. Targeting HDGF may be a novel strategy for Ewing sarcoma/PNET treatment.
Category: Bone & Soft Tissue
Tuesday, March 5, 2013 1:00 PM
Poster Session IV # 11, Tuesday Afternoon